We aspire to enhance the well-being of young T1 diabetes patients for life and reduce their risk of developing severe complications. Our solution is DUN T1, an efficient, self-administered early-stage therapy.
We develop an efficient therapy to delay T1 diabetes progression from a sustainable source that is safer for patients and better for our planet.
From a medical perspective, utilizing phytochemicals from botanical origins to treat autoimmune conditions is preferred to a biological intervention, as it guarantees a higher safety profile and has fewer adverse effects.
From an ecological viewpoint, we focus on solutions that can overcome the challenges of climate change. We have found that phytochemicals sourced in botanicals grown in extreme environmental conditions (a dry desert, in our case) allow a stable and sustainable pharmaceutical supply chain.
We center on the inherent advantages of phytochemical-based medications.
Many widely-known drugs today (Ephedrine, Metformin, Atropine etc.) were initially developed from plant sources. However, in recent decades, pharmaceutical innovation has shifted away from phyto-chemical-based medicines and tended to focus on biological treatments.
We aim to produce botanically sourced therapies by utilizing safe and well-established methods that have been perfected by humans for millennia. Our work also helps pave new regulatory and scientific paths for other botanics-based medicines.
Fluid congestion, poisoning | Botanical Source - Atropa Belladonna
Pain and fever symptoms | Botanical Source - Spirea Ulmaria
Type-2 diabetes mellitus | Botanical Source - Galega Officinalis
Fluid congestion, poisoning | Botanical Source - Atropa Belladonna
A proactive approach to an impending health crisis
Dun T1 is the right therapy at the right time.
T1 Diabetes is rapidly becoming a global health concern. New diagnosis numbers have risen steadily since the 1980s and continue to grow, while the average diagnosis age seems to drop. Patients, caretakers, and healthcare systems must bear the costs of lifetime care and complications over more years than ever before.
In these circumstances, we believe that a proactive approach is necessary: One that involves screening and early detection on one hand and practical, affordable, and sustainable intravenous therapies on the other.
For millions of young patients around the globe, timely access to DUN T1 could make the difference between decades of disease management and years - Possibly a lifetime - of freedom.
Industrialized countries require more resources for T1 diabetes care than ever before.
Data from the last decades shows that T1 diabetes is growing globally at an alarming rate. Children and younger people especially seem to be diagnosed more than ever - Though this may be partly due to better screening processes. In this context, The New Zealand Medical Journal published a 2015 study concluding that of all types of diabetes, type 1 is most likely to affect the younger population, “irrespective of ethnicity and socioeconomic status.”
-
In the United States, about 2.1 million people are expected to be diagnosed with type 1 diabetes by 2040. The disease is growing at 2.9% per year versus population growth of 0.8% per year.
-
There was a 21 percent increase in people diagnosed with type 1 diabetes between 2001 and 2009 under 20.
-
In Canada, the incidence rate of type 1 among children 1-9 years old doubled over ten years from 1998-2009 from 0.1 percent to 0.2 percent.
-
Similar numbers were reported in New Zealand, where the incidence rate more than doubled between 1990 and 2009. It went from 10.9 per 100,000 among children aged 0-14 to 22.5 per 100,000 in 2009.
-
In the Netherlands, about 5% of the population live with T1 diabetes, and the incidence rate in children doubled between 1978 and 2011.
-
In Germany, the incidence rate of type 1 diabetes increased the most in children 10–14 years old compared to any other age group between 1999-2014.
-
Research in China found that almost 25% of new diagnoses between 2010-2013 were among people younger than 15, and the 10-14 age group had the peak incidence rate.
T1 diabetes is expensive to treat due to lifetime care costs and lost income. While in some countries, the healthcare system carries all or most of the financial burden; in others, patients must fund daily treatments and devices they can’t always afford.
-
In the United States alone, there are roughly $16 billion in type 1 diabetes-associated healthcare expenditures and yearly lost income.
-
Preliminary data from T1International’s 2018 access and supply survey says one of every four US respondents has rationed insulin due to cost.
-
In the UK, the average diabetes cost share per month is 1.4 percent, according to T1International’s 2016 survey responses.
Developing countries urgently require an accessible solution to T1 Diabetes.
The spread of T1 diabetes isn't limited to the Western world. Many countries in Central and South America, Africa, and Asia experience similar growth in occurrence and diagnosis rates, with added complexity due to insufficient medical and financial resources.
Since many people in developing countries live below the poverty line, countless children cannot access optimal care and might face a considerably shortened lifespan. In larger cities, a child diagnosed with type 1 diabetes has an average life expectancy of around 20 years. However, it may go down to as low as one year in rural areas. Even with public health insurance schemes, some families cannot afford care. In India, for example, it was found that the average cost share is nearly 80 percent of the monthly income for someone with type 1 diabetes.
Another aspect of the matter is the lack of medical infrastructure and access to clinicians, proper technologies, or facilities. These resources are still scarce in many regions, rendering adequate disease management nearly impossible for lower-income households. In Argentina, for example, essential technologies like blood and oral glucose tests, A1c measurements, and urine tests are not generally available in the public health sector.
These facts highlight the urgency to develop a therapy like DUN T1, that was developed with these very issues in mind:
-
Easy oral administration that does not require ongoing medical supervision or hospitalization
-
Reversing or delaying the onset of the disease means saving precious time and resources - potentially saving patients years’ worth of care costs